Farnesoid X receptor (FXR) has been previously identified as an important drug target for nonalcoholic steatohepatitis (NASH) and other related diseases, with GW-4064 being the first nonsteroidal FXR ...

Researchers from Guangdong Pharmaceutical University and affiliated organizations have discovered novel farnesoid X receptor (FXR) agonists as candidates for the treatment of nonalcoholic ...